 |
|
Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents
Min Hee Hong
Kidney Res Clin Pract. 2021;40(3):344-354. Published online 2021 Jul 8 DOI: https://doi.org/10.23876/j.krcp.21.037
|
|
Citations to this article as recorded by
 Role for calcineurin inhibitor in tyrosine kinase inhibitor-induced focal segmental glomerulosclerosis
Benjamin R Teruel, Evelyn T Bruner, Blaithin A McMahon
Journal of Onco-Nephrology.2023; 7(2): 90. CrossRef From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
Laura Fabbri, Alessandro Di Federico, Martina Astore, Virginia Marchiori, Agnese Rejtano, Renata Seminerio, Francesco Gelsomino, Andrea De Giglio
Diagnostics.2023; 14(1): 48. CrossRef Immune checkpoint inhibitor-induced acute tubulointerstitial nephritis
Hui Zhuan Tan, Joycelyn Jie Xin Lee, Chon Jun Jason Choo, Alwin Hwai Liang Loh
Kidney Research and Clinical Practice.2022; 41(1): 128. CrossRef Role of T cells in ischemic acute kidney injury and repair
Kyungho Lee, Hye Ryoun Jang
The Korean Journal of Internal Medicine.2022; 37(3): 534. CrossRef Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
Sara Verdura, José Antonio Encinar, Salvador Fernández-Arroyo, Jorge Joven, Elisabet Cuyàs, Joaquim Bosch-Barrera, Javier A. Menendez
International Journal of Molecular Sciences.2022; 23(17): 9986. CrossRef
|